Thus, our data suggests that beneficial effects of statin, ACE inhibitors, and ARBs on mortality in patients admitted with pneumonia may not be due to prevention of future cardiac events, but other mechanisms. This evidence concerns the gene ACE and susceptibility to pneumonia measurement.